Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience

Drug Profile

Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience

Alternative Names: Atorvastatin - Oxford Pharmascience; OXP 003; OXP 004; Safestat™ Atorvastatin; Safestat™ Simvastatin; Simvastatin - Oxford Pharmascience; Statins modified release - Oxford Pharmascience

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford Pharmascience
  • Class Amides; Fluorobenzenes; Heptanoic acids; Naphthalenes; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 09 Nov 2016 Development of a new colon-targeted formulation of atorvastatin for cardiovascular disorders is ongoing in United Kingdom
  • 30 Apr 2014 Oxford Pharmascience plans a phase I trial of its atorvastatin product for Hyperlipidaemia in the United Kingdom
  • 17 Mar 2014 Research programme: HMG CoA reductase inhibitors controlled release - Oxford Pharmascience is available for licensing as of 17 Mar 2014. http://www.oxfordpharmascience.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top